Mucin binding reduces colistin antimicrobial activity

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 10, 2015, Pages 5925-5931

  Huang, Johnny X ^a   Blaskovich, Mark A T ^a   Pelingon, Ruby ^a   Ramu, Soumya ^a   Kavanagh, Angela ^a   Elliott, Alysha G ^a   Butler, Mark S ^a   Montgomery, A Bruce ^b   Cooper, Matthew A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Cardeas Pharma   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; COLISTIN; DAPTOMYCIN; MUCIN; POLYMYXIN B; TOBRAMYCIN; ANTIINFECTIVE AGENT; CULTURE MEDIUM; DIALYSIS FLUID; PROTEIN BINDING;

ANTIMICROBIAL ACTIVITY; ARTICLE; GRAM NEGATIVE BACTERIUM; LIQUID CHROMATOGRAPHY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; TANDEM MASS SPECTROMETRY; ACINETOBACTER BAUMANNII; ANIMAL; CHEMISTRY; CULTURE MEDIUM; DIALYSIS; DRUG EFFECTS; ESCHERICHIA COLI; GROWTH, DEVELOPMENT AND AGING; KLEBSIELLA PNEUMONIAE; METABOLISM; MICROBIAL SENSITIVITY TEST; PHARMACOLOGY; PIG; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

ACINETOBACTER BAUMANNII; ANIMALS; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; COLISTIN; CULTURE MEDIA; DAPTOMYCIN; DIALYSIS; DIALYSIS SOLUTIONS; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MUCINS; POLYMYXIN B; PROTEIN BINDING; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; SWINE; TOBRAMYCIN;

EID: 84942875562     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00808-15     Document Type: Article

References (45)

1. Nation RL, Velkov T, Li J. 2014. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis 59:88-94. http://dx.doi.org/10.1093/cid/ciu213.
2. Kassamali Z, Rotschafer JC, Jones RN, Prince RA, Danziger LH. 2013. Polymyxins: wisdom does not always come with age. Clin Infect Dis 57:877-883. http://dx.doi.org/10.1093/cid/cit367.
3. Nation RL, Li J, Turnidge JD. 2013. The urgent need for clear and accurate information on the polymyxins. Clin Infect Dis 57:1656-1657. http://dx.doi.org/10.1093/cid/cit522.
4. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. 2006. Colistin: the reemerging antibiotic for multidrugresistant Gram-negative bacterial infections. Lancet Infect Dis 6:589-601. http://dx.doi.org/10.1016/S1473-3099 (06) 70580-1.
5. Jensen T, Pedersen SS, Garne S, Heilmann C, Høiby N, Koch C. 1987. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 19:831-838. http://dx.doi.org/10.1093/jac/19.6.831.
6. Döring G, Conway SP, Heijerman HG, Hodson ME, Høiby N, Smyth A, Touw DJ. 2000. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 16:749-767. http://dx.doi.org/10.1034/j.1399-3003.2000.16d30.x.
7. Gurjar M. 2015. Colistin for lung infection: an update. J Intensive Care 3:3. http://dx.doi.org/10.1186/s40560-015-0072-9.
8. Velkov T, Abdul Rahim N, Zhou QT, Chan HK, Li J. 2015. Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead. Adv Drug Deliv Rev 85:65-68. http://dx.doi.org/10.1016/j.addr.2014.11.004.
9. Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. 2014. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Resp Crit Care Med 189:975-982. http://dx.doi.org/10.1164/rccm.201312-2208OC.
10. Michalopoulos A, Fotakis D, Virtzili S, Vletsas C, Raftopoulou S, Mastora Z, Falagas ME. 2008. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med 102:407-412. http://dx.doi.org/10.1016/j.rmed.2007.10.011.
11. He H, Li JC, Nation RL, Jacob J, Chen G, Lee HJ, Tsuji BT, Thompson PE, Roberts K, Velkov T, Li J. 2013. Pharmacokinetics of four different brands of colistimethate and formed colistin in rats. J Antimicrob Chemother 68:2311-2317. http://dx.doi.org/10.1093/jac/dkt207.
12. National Institutes of Health. April 2015. ClinicalTrials.gov identifier NCT01863719: aerosolized and intravenous colistin in healthy adults. https://clinicaltrials.gov/ct2/show/NCT01863719.
13. Westerman EM, de Boer AH, Le Brun PP, Touw DJ, Frijlink HW, Heijerman HG. 2007. Dry powder inhalation of colistin sulphomethate in healthy volunteers: a pilot study. Int J Pharm 335:41-45. http://dx.doi.org/10.1016/j.ijpharm.2006.11.021.
14. Westerman EM, De Boer AH, Le Brun PP, Touw DJ, Roldaan AC, Frijlink HW, Heijerman HG. 2007. Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. J Cyst Fibros 6:284-292. http://dx.doi.org/10.1016/j.jcf.2006.10.010.
15. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. 2005. Evaluation of colistin as an agent against multiresistant Gram-negative bacteria. Int J Antimicrob Agents 25:11-25. http://dx.doi.org/10.1016/j.ijantimicag.2004.10.001.
16. Das D, Buyck J, Van Bambeke F, Lorent J, Mingeot-Leclercq M, Gobin P, Couet W, Tulkens PM. 2011. Comparative assessment of antibacterial and cytotoxic effects of colistin (CST) colistin methanesulfonate (CMS) and polymyxin B (PMB) using Pseudomonas aeruginosa, macrophages and renal cells, and liposomes, abstr F2-170. 51st Intersci Conf Antimicrob Agents Chemother, 17 to 20 September 2011, Chicago, IL. http://www.ab stractsonline.com/plan/ViewAbstract.aspx?mID=2789&sKey=5b319c8 7-0c75-4ca9-9ee9-762aa8a4a65c&cKey=e1f391f6-ef61-4e88-8613-537c bdfd7a9e&mKey=0c918954-d607-46a7-8073-44f4b537a439.
17. Van Devanter DR, Rose LM, Sprugel KH. 2001. 28-day inhalation toxicology of polymyxin E1, the major active component of colistin, in rats and dogs, poster P236. 24th European Cystic Fibrosis Congress, Vienna, Austria.
18. Le Brun PP, de Boer AH, Mannes GP, de Fraíture DM, Brimicombe RW, Touw DJ, Vinks AA, Frijlink HW, Heijerman HG. 2002. Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur J Pharm Biopharm 54:25-32. http://dx.doi.org/10.1016/S0939-6411 (02) 00044-9.
19. Westerman EM, Le Brun PP, Touw DJ, Frijlink HW, Heijerman HG. 2004. Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J Cyst Fibros 3:23-28. http://dx.doi.org/10.1016/j.jcf.2003.12.005.
20. McCoy KS. 2007. Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome. N Engl J Med 357:2310-2311. http://dx.doi.org/10.1056/NEJMc071717.
21. Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, van Koningsbruggen S, Grasemann H. 2006. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 57:306-311. http://dx.doi.org/10.1093/jac/dki461.
22. Touw DJ, Jacobs FA, Brimicombe RW, Heijerman HG, Bakker W, Briemer DD. 1997. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 41:184-187.
23. Le Brun PP, Vinks AA, Touw DJ, Hekelaar N, Mannes GP, Brimicombe RW, Frijlink EH, Heijerman HG. 1999. Can tobramycin inhalation be improved with a jet nebulizer? Ther Drug Monit 21:618-624. http://dx.doi.org/10.1097/00007691-199912000-00007.
24. Wallace SJ, Li J, Rayner CR, Coulthard K, Nation RL. 2008. Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients. Antimicrob Agents Chemother 52:3047-3051. http://dx.doi.org/10.1128/AAC.00103-08.
25. Hunt BE, Weber A, Berger A, Ramsey B, Smith AL. 1995. Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrob Agents Chemother 39:34-39. http://dx.doi.org/10.1128/AAC.39.1.34.
26. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL. 1985. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 132:761-765.
27. King P, Lomovskaya O, Griffith DC, Burns JL, Dudley MN. 2010. In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. Antimicrob Agents Chemother 54:143-148. http://dx.doi.org/10.1128/AAC.00248-09.
28. Ramphal R, Lhermitte M, Filliat M, Roussel P. 1988. The binding of anti-pseudomonal antibiotics to macromolecules from cystic fibrosis sputum. J Antimicrob Chemother 22:483-490. http://dx.doi.org/10.1093/jac/22.4.483.
29. Yapa S W S, Li J, Patel K, Wilson JW, Dooley MJ, George J, Clark D, Poole S, Williams E, Porter CJ, Nation RL, McIntosh MP. 2014. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob Agents Chemother 58:2570-2579. http://dx.doi.org/10.1128/AAC.01705-13.
30. Voynow JA, Rubin BK. 2009. Mucins, mucus, and sputum. Chest 135:505-512. http://dx.doi.org/10.1378/chest.08-0412.
31. Roussel P, Degand P, Lamblin G, Laine A, Lafitte JJ. 1978. Biochemical definition of human tracheobronchial mucus. Lung 154:241-260.
32. Sriramulu DD, Lünsdorf H, Lam JS, Römling U. 2005. Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung. J Med Microbiol 54(Part 7):667-676. http://dx.doi.org/10.1099/jmm.0.45969-0.
33. Bucki R, Namiot DB, Namiot Z, Savage PB, Janmey PA. 2008. Salivary mucins inhibit antibacterial activity of the cathelicidin-derived LL-37 peptide but not the cationic steroid CSA-13. J Antimicrob Chemother 62:329-335. http://dx.doi.org/10.1093/jac/dkn176.
34. Sarker SD, Nahar L, Kumarasamy Y. 2007. Microtitre plate-based antibacterial assay incorporating resazurin as an indicator of cell growth, and its application in the in vitro antibacterial screening of phytochemicals. Methods 42:321-324. http://dx.doi.org/10.1016/j.ymeth.2007.01.006.
35. Mann CM, Markham JL. 1998. A new method for determining the minimum inhibitory concentration of essential oils. J Appl Microbiol 84:538-544. http://dx.doi.org/10.1046/j.1365-2672.1998.00379.x.
36. Mizgerd JP, Skerrett SJ. 2008. Animal models of human pneumonia. Am J Physiol Lung Cell Mol Physiol 294:L387-L398. http://dx.doi.org/10.1152/ajplung.00330.2007.
37. Liu X, Driskell RR, Engelhardt JF. 2004. Airway glandular development and stem cells. Curr Top Dev Biol 64:33-56. http://dx.doi.org/10.1016/S0070-2153 (04) 64003-8.
38. Ball P. 1990. Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches. J Antimicrob Chemother 26(Suppl F):165-179.
39. Andersson DI, Hughes D. 2014. Microbiological effects of sublethal levels of antibiotics. Nat Rev Microbiol 12:465-478. http://dx.doi.org/10.1038/nrmicro3270.
40. Sader HS, Rhomberg PR, Flamm RK, Jones RN. 2012. Use of a surfactant (polysorbate 80) to improve MIC susceptibility testing results for polymyxin B and colistin. Diagn Microbiol Infect Dis 74:412-414. http://dx.doi.org/10.1016/j.diagmicrobio.2012.08.025.
41. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. 2005. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191:2149-2152. http://dx.doi.org/10.1086/430352.
42. Coulthard K. 2008. Maximizing the efficacy and safety of colistimethate therapy. Pediatr Pulmonol 43(Suppl):193-195. http://dx.doi.org/10.1002/ppul.20938.
43. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. 2015. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis 15:225-234. http://dx.doi.org/10.1016/S1473-3099 (14) 70850-3.
44. Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM. 2012. Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther 10:917-934. http://dx.doi.org/10.1586/eri.12.78.
45. Qureshi ZA, Hittle LE, O'Hara JA, Rivera JI, Syed A, Shields RK, Pasculle AW, Ernst RK, Doi Y. 2015. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis 60:1295-1303. http://dx.doi.org/10.1093/cid/civ048.